Conversion therapy for intrahepatic cholangiocarcinoma: status and perspectives

Abstract

CLC Number:

R735.7

FANG Cheng, XIA Yong, WANG Kui, SHEN Feng. Conversion therapy for intrahepatic cholangiocarcinoma: status and perspectives[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 107-112.

References54

[1]	Massani M, Bonariol L, Stecca T. Hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma, a comprehensive review[J]. J Clin Med, 2021, 10(12):2552. doi:10.3390/jcm10122552 URL
[2]	Nakanuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept[J]. World J Hepatol, 2010, 2(12):419-427. doi:10.4254/wjh.v2.i12.419pmid:21191517
[3]	Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management[J]. Cancer Lett, 2016, 379(2):198-205. doi:10.1016/j.canlet.2015.09.008pmid:26409434
[4]	Benson AB, D′Angelica MI, Abbott DE, et al. Hepatobi-liary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565. doi:10.6004/jnccn.2021.0022 URL
[5]	Groot Koerkamp B, Wiggers JK, Allen PJ, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection[J]. J Am Coll Surg, 2015, 221(6):1041-1049. doi:10.1016/j.jamcollsurg.2015.09.005 URL
[6]	Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and trans-lational advances[J]. Hepatology, 2019, 69(4):1803-1815. doi:10.1002/hep.30289 URL
[7]	Tan JC, Coburn NG, Baxter NN, et al. Surgical management of intrahepatic cholangiocarcinoma-a population-based study[J]. Ann Surg Oncol, 2008, 15(2):600-618. doi:10.1245/s10434-007-9627-x URL
[8]	孙惠川谢青, 荚卫东, 等. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(06):618-632. doi:10.19538/j.cjps.issn1005-2208.2021.06.02
[9]	Yamaoka K, Kawaoka T, Aikata H, et al. Complete response for advanced hepatocellular carcinoma by conversion surgery therapy following a good response of regorafenib despite rapid progressive disease with sorafenib[J]. Intern Med, 2021, 60(13):2047-2053. doi:10.2169/internalmedicine.5870-20 URL
[10]	Wu Z, Fang H. Efficacy of paclitaxel and S-1 combined with apatinib in the conversion therapy for unresectable advanced gastric cancer[J]. J BUON, 2021, 26(4):1485-1490.
[11]	Liu T, Chang W, Wang J, et al. Efficacy of conversion therapy on initially unresectable locally advanced rectal cancer[J]. J Cancer, 2021, 12(14):4418-4423. doi:10.7150/jca.53824 URL
[12]	Fong ZV, Brownlee SA, Qadan M, et al. The clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines[J]. Ann Surg Oncol, 2021, 28(5):2660-2674. doi:10.1245/s10434-021-09671-ypmid:33646431
[13]	Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2020, 27(10):3729-3737. doi:10.1245/s10434-020-08486-7 URL
[14]	Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7):839-847. doi:10.1002/bjs.10641pmid:28858392
[15]	Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6):824-830. doi:10.1001/jamaoncol.2019.0270 URL
[16]	Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 72(2):364-377. doi:S0168-8278(19)30711-1pmid:31954498
[17]	Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma[J]. Br J Cancer, 2019, 120(2):165-171. doi:10.1038/s41416-018-0334-0 URL
[18]	Bekaii-Saab TS, Valle JW, Van Cutsem E, et al. FIGHT-302: first-line pemigatinibvsgemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements[J]. Future Oncol, 2020, 16(30):2385-2399. doi:10.2217/fon-2020-0429 URL
[19]	Ma B, Meng H, Tian Y, et al. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma[J]. BMC Cancer, 2020, 20(1):318. doi:10.1186/s12885-020-06804-6 URL
[20]	Loaiza-Bonilla A, Clayton E, Furth E, et al. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine[J]. Ecancermedicalscience, 2014, 8:479. doi:10.3332/ecancer.2014.479pmid:25435907
[21]	Overman MJ, Lonardi S, Wong KYM, et al. Durable cli-nical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8):773-779.
[22]	Feng K, Liu Y, Zhao Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase Ⅱ study[J]. J Immunother Cancer, 2020, 8(1):e000367.
[23]	Zhang Q, Liu X, Wei S, et al. Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase Ⅱ study[J]. Front Oncol, 2021, 11:751391.
[24]	Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J]. World J Surg, 2018, 42(9):2910-2918. doi:10.1007/s00268-018-4558-1pmid:29511872
[25]	Chen C, Liu Y, Cui B. Effect of radiotherapy on T cell and PD-1/PD-L1 blocking therapy in tumor microenvironment[J]. Hum Vaccin Immunother, 2021, 17(6):1555-1567. doi:10.1080/21645515.2020.1840254 URL
[26]	Liu X, Yao J, Song L, et al. Local and abscopal respon-ses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade[J]. J Immunother Cancer, 2019, 7(1):204. doi:10.1186/s40425-019-0692-z URL
[27]	Liu ZL, Liu X, Peng H, et al. Anti-PD-1 immunotherapy and radiotherapy for stage Ⅳ intrahepatic cholangiocarcinoma: a case report[J]. Front Med (Lausanne), 2020, 7:368.
[28]	Cercek A, Boerner T, Tan BR, et al. Assessment of he-patic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2020, 6(1):60-67. doi:10.1001/jamaoncol.2019.3718 URL
[29]	Zhou TY, Zhou GH, Zhang YL, et al. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma[J]. J Cancer, 2020, 11(15):4534-4541. doi:10.7150/jca.39410 URL
[30]	Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment[J]. Ann Surg Oncol, 2015, 22(9):3102-3108. doi:10.1245/s10434-014-4365-3pmid:25623598
[31]	Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2020, 6(1):51-59. doi:10.1001/jamaoncol.2019.3702 URL
[32]	Aloia TA. Associating liver partition and portal vein ligation for staged hepatectomy: portal vein embolization should remain the gold standard[J]. JAMA Surg, 2015, 150(10):927-928. doi:10.1001/jamasurg.2015.1646 URL
[33]	Tustumi F, Ernani L, Coelho FF, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis[J]. HPB (Oxford), 2018, 20(12):1109-1118. doi:10.1016/j.hpb.2018.06.1798 URL
[34]	Wang Z, Peng Y, Hu J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients[J]. Ann Surg, 2020, 271(3):534-541. doi:10.1097/SLA.0000000000002942 URL
[35]	Peng C, Li C, Liu C, et al. The outcome of the HCC patients underwent ALPPS: retrospective study[J]. Medicine (Baltimore), 2019, 98(38):e17182.
[36]	Li PP, Huang G, Jia NY, et al. Associating liver partition and portal vein ligation for staged hepatectomyversussequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related he-patocellular carcinoma: a randomized comparative study[J]. Hepatobiliary Surg Nutr, 2022, 11(1):38-51. doi:10.21037/hbsn-20-264 URL
[37]	Li J, Moustafa M, Linecker M, et al. ALPPS for locally advanced intrahepatic cholangiocarcinoma: did aggressive surgery lead to the oncological benefit? an international multi-center study[J]. Ann Surg Oncol, 2020, 27(5):1372-1384. doi:10.1245/s10434-019-08192-z URL
[38]	Sparrelid E, Gilg S, Brismar TB, et al. Rescue ALPPS is efficient and safe after failed portal vein occlusion in patients with colorectal liver metastases[J]. Langenbecks Arch Surg, 2017, 402(1):69-75. doi:10.1007/s00423-016-1524-y URL
[39]	Ulmer TF, de Jong C, Andert A, et al. ALPPS procedure in insufficient hypertrophy after portal vein embolization (PVE)[J]. World J Surg, 2017, 41(1):250-257. doi:10.1007/s00268-016-3662-3pmid:27464917
[40]	Buac S, Schadde E, Schnitzbauer AA, et al. The many faces of ALPPS: surgical indications and techniques among surgeons collaborating in the international registry[J]. HPB (Oxford), 2016, 18(5):442-448. doi:10.1016/j.hpb.2016.01.547 URL
[41]	Oldhafer KJ, Stavrou GA, van Gulik TM, et al. ALPPS-where do we stand, where do we go? eight recommendations from the first international expert meeting[J]. Ann Surg, 2016, 263(5):839-841. doi:10.1097/SLA.0000000000001633pmid:26756771
[42]	何拯, 颜海燕, 付健, 等. 三明治技术在腹主动脉瘤累及髂总动脉腔内治疗中保留髂内动脉的疗效分析[J]. 介入放射学杂志, 2020, 29(5):449-452.
[43]	Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumabvs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2021, 76(4):862-873. doi:10.1016/j.jhep.2021.11.030 URL
[44]	Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26):2960-2970. doi:10.1200/JCO.20.00808 URL
[45]	Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3):965-981. doi:10.1002/hep.31092 URL
[46]	Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma[J]. Cancer Cell, 2017, 32(1):57-70. doi:S1535-6108(17)30205-2pmid:28648284
[47]	Sia D, Hoshida Y, Villanueva A, et al. Integrative mole-cular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4):829-840. doi:10.1053/j.gastro.2013.01.001 URL
[48]	Dong L, Lu D, Chen R, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahe-patic cholangiocarcinoma[J]. Cancer Cell, 2022, 40(1):70-87. doi:10.1016/j.ccell.2021.12.006 URL
[49]	Chow FC, Chok KS. Colorectal liver metastases: an update on multidisciplinary approach[J]. World J Hepatol, 2019, 11(2):150-172. doi:10.4254/wjh.v11.i2.150 URL
[50]	De Greef K, Rolfo C, Russo A, et al. Multisciplinary management of patients with liver metastasis from co-lorectal cancer[J]. World J Gastroenterol, 2016, 22(32):7215-7225. doi:10.3748/wjg.v22.i32.7215 URL
[51]	Charriere B, Muscari F, Maulat C, et al. Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings[J]. J Surg Oncol, 2017, 115(3):330-336. doi:10.1002/jso.24500pmid:27813094
[52]	王之伟, 郑俊玲, 李江涛, 等. 肝内胆管癌的转化治疗[J]. 生物医学转化, 2020, 1(1):26-34.
[53]	Miyata T, Yamashita YI, Yamao T, et al. Clinical benefits of lymph node dissection in intrahepatic cholangiocarcinoma: a retrospective single-institution study[J]. Anticancer Res, 2017, 37(5):2673-2677. doi:10.21873/anticanres.11615 URL
[54]	吴军, 琴瀚姣, 盛基尧, 等. 不可切除肝内胆管细胞癌诊疗策略[J]. 中华肝脏外科手术学电子杂志, 2021, 10(1):1-5.

Conversion therapy for intrahepatic cholangiocarcinoma: status and perspectives

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References54

Related Articles15

Recommended Articles

Metrics

Comments

[1]	YE Feng, GONG Xiaoyong, REN Jiajun, CAI Qiang, CHEN Sheng.Application of ERCP in diagnosis and treatment of biliary complications during perioperative period of primary liver cancer[J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 355-360.
[2]	CHANG Jessica, CHEN Xuxiao, CHEN Yongjun.Role of the spleen in patients with liver cancer and cirrhosis[J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 394-398.
[3]	ZHANG Hui, GONG Ling, GUO Qian, LUO Yan.Retrospective study on sugammadex for reversal of neuromuscular blockade after radiofrequency ablation of hepatic carcinoma under general anesthesia[J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 72-76.
[4]	ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing.Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482.
[5]	YIN Yanjiang, LUO Zhiwen, CHEN Xiao, ZHANG Yefan, HUANG Zhen, ZHAO Hong, ZHAO Jianjun, LI Zhiyu, ZHOU Jianguo, CAI Jianqiang, BI Xinyu.Relationship between surgical margin and prognosis of patients with intrahepatic cholangiocarcinoma[J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 221-228.
[6]	CHEN Congyan, WANG Junqing, CHEN Yongjun.Gut microbiota and mechanism of liver cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 256-260.
[7]	LIU Shenyang, TANG Zhaohui, QUAN Zhiwei.Advances in surgical treatment of intrahepatic cholangiocarcinoma[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 100-106.
[8]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 93-94.
[9]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 95-99.
[10]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118.
[11]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122.
[12]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 123-127.
[13]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130.
[14]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133.
[15]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 134-138.